Tipsheet
What matters at India’s listed companies
Concalls · Life Sciences Tools

Tarsons Products delays plant commissioning as margins face pressure

Management now expects FY27 net profit margins to hit just 4-5% as depreciation costs rise and raw material prices remain elevated.

3 earlier stories on Tarsons Products Ltd.
Mkt cap₹1,184 cr
P/E52.26×
ROE4.72%
Debt / eq.0.52
4-5% Projected FY27 net profit margin

What's new

  • Peak standalone depreciation guidance raised to ₹105-110 cr for FY25.
  • Amta and Panchla plant commissioning delayed to H1 FY27.
  • Q4 gross margins slipped to 68.5% as raw material costs surged 60-70%.

Why this matters

The company is caught in a difficult capex cycle where rising depreciation and interest costs are colliding with margin compression. The delay in new capacity means the expected revenue lift from these investments is pushed further out, leaving profitability thin for the next year.

What we're watching

  • Whether raw material costs stabilize or continue to weigh on margins.
  • Updates on the revised H1 FY27 commissioning timeline for new units.
  • The impact of interest charges on cash flow as capex projects go live.

The full read

Tarsons Products is facing a difficult transition as its latest capex cycle hits the balance sheet. Management raised its peak standalone depreciation guidance to ₹105-110 crore for the current year, up from the previous ₹100-105 crore estimate, as ₹158 crore in capital work-in-progress is moved to the books. At the same time, the company pushed back the commissioning of its new Amta and Panchla manufacturing units to the first half of FY27. Compounding these delays, raw material costs have spiked 60-70% above normal levels. This cost pressure dragged fourth-quarter gross margins down to 68.5%, compared to the full-year average of 71%. With higher depreciation and interest charges looming, management now expects net profit margins to settle in the 4-5% range for FY27. The company is effectively trading near-term profitability for future capacity, but the timeline for that capacity has just grown longer.

Questions answered

Why did Tarsons raise its depreciation guidance?
The company is capitalizing ₹158 crore of capital work-in-progress. This shift pushes peak standalone depreciation to a range of ₹105-110 crore for the current financial year.
What is the status of the new manufacturing units?
Commissioning for the Amta and Panchla units is now set for the first half of FY27. This is a delay from the previous target of the fourth quarter of FY26.
How are raw material costs affecting the bottom line?
Raw material costs have jumped 60-70% above normalized levels. This surge compressed fourth-quarter gross margins to 68.5%, down from the full-year average of 71%.
What is the outlook for FY27 profitability?
Management anticipates net profit margins in the low single-digit range of 4-5%. This pressure stems from the combination of elevated depreciation and interest charges.
Mentioned: Amta · Panchla · FY27
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

  1. Today · 1:33 PM IST Tarsons Products delays plant commissioning as margins face pressure
  2. 3d ago Tarsons profit drops 52% as finance costs and excess pay weigh
  3. 3d ago Tarsons Products profit drops 52% as finance and depreciation costs bite
  4. 3d ago Tarsons Products profits halved as depreciation and interest bite